Early access
Sign in
Taking people in United StatesNo phase

Nerve Damage From Enfortumab Vedotin in People With Urothelial Cancer

Studies how nerve test results change in people with urothelial cancer receiving enfortumab vedotin.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 7 sites
Trial code
Registry title
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Status
Recruiting
People taking part
50 people, planned
Started
20 Jan 2026
Expected to end
20 Jan 2028
Type of study
Observational
Treatments tested
  • Non-therapeutic Nerve Conduction Studies
  • Non-therapeutic assessment of patient-reported neuropathy
Record updated
29 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with urothelial cancer who are planning to start enfortumab vedotin, with or without pembrolizumab. It studies how nerve test results change during treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Urothelial carcinoma confirmed by tissue or cell tests (histology or cytology). The title mentions metastatic or muscle-invasive disease.
Earlier treatment
Must be planning to start enfortumab vedotin, with or without pembrolizumab. Must not have had enfortumab vedotin before.

Main reasons for not taking part

  • Has already had enfortumab vedotin
  • Cannot understand or follow the study procedures
  • Cannot speak and read English well enough to give consent and fill in the questionnaires
  • Pregnant women
  • Students or employees of the study institution, prisoners, and institutionalized people

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant
  • Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires
  • Age ≥ 18 years at the time of consent
  • ECOG Performance Status of ≤ 3 within 28 days prior to consent
  • Histological or cytologically confirmed urothelial carcinoma
  • Patients must be planned to start systemic therapy with enfortumab vedotin
  • At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab

Who cannot take part

  • Having previously received enfortumab vedotin
  • Subjects meeting any of the criteria below may not participate in the study:
  • Inability of the subject to understand and comply with study procedures
  • Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects)

Where in United States

  • Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Samuel Funt, MDTaking people
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Samuel Funt, MDTaking people
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Samuel Funt, MDTaking people
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Samuel Funt, MDTaking people
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Samuel Funt, MDTaking people
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, United StatesContact: Samuel Funt, MDTaking people
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)Rockville Centre, United StatesContact: Samuel Funt, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)

The group in the trial

  • Participants With Urothelial Carcinoma

    Participants will have histological or cytologically confirmed urothelial carcinoma

    Treatment: Non-therapeutic Nerve Conduction Studies and Non-therapeutic assessment of patient-reported neuropathy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin
Plain-language title
Nerve Damage From Enfortumab Vedotin in People With Urothelial CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 May 2026